{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:59:35Z","timestamp":1778209175728,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ygyno.2018.12.021","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T22:03:23Z","timestamp":1546553003000},"page":"612-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing"],"prefix":"10.1016","volume":"152","author":[{"given":"Kelly","family":"Fulk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Milam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Yussuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Helen","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"LaDuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Stany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.12.021_bb0005","series-title":"Cancer Facts and Figures 2017","author":"American Cancer Society","year":"2017"},{"issue":"1","key":"10.1016\/j.ygyno.2018.12.021_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Committee SGOCP. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/jmg.39.4.225","article-title":"Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility","volume":"39","author":"de Jong","year":"2002","journal-title":"J. Med. Genet."},{"issue":"9","key":"10.1016\/j.ygyno.2018.12.021_bb0020","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0025","doi-asserted-by":"crossref","first-page":"219012","DOI":"10.1155\/2015\/219012","article-title":"Hereditary syndromes manifesting as endometrial carcinoma: how can pathological features aid risk assessment?","volume":"2015","author":"Wong","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0030","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2018.12.021_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","article-title":"A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients","volume":"17","author":"Lincoln","year":"2015","journal-title":"J. Mol. Diagn."},{"issue":"5","key":"10.1016\/j.ygyno.2018.12.021_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097408","article-title":"The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay","volume":"9","author":"Chong","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ygyno.2018.12.021_bb0045","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2018.12.021_bb0050","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/modpathol.2016.135","article-title":"Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort","volume":"29","author":"Ring","year":"2016","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.12.021_bb0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10689-014-9722-7","article-title":"Genetics of endometrial cancer","volume":"13","author":"Shai","year":"2014","journal-title":"Familial Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2018.12.021_bb0060","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1245\/s10434-014-4193-5","article-title":"Risk factors for the development of uterine cancer in breast cancer survivors: an army of women study","volume":"22","author":"Torres","year":"2014","journal-title":"Ann. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2018.12.021_bb0065","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.ygyno.2018.12.021_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0075","doi-asserted-by":"crossref","first-page":"2469523","DOI":"10.1155\/2016\/2469523","article-title":"Beyond DNA: an integrated and functional approach for classifying germline variants in breast cancer genes","volume":"2016","author":"Pesaran","year":"2016","journal-title":"Int. J. Breast Cancer."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0080","article-title":"Somatic TP53 variants frequently confound germ-line testing results","author":"Weitzel","year":"2017","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2018.12.021_bb0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"13","key":"10.1016\/j.ygyno.2018.12.021_bb0090","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1245\/s10434-014-3711-9","article-title":"Can breast surgeons provide breast cancer genetic testing? An American Society of Breast Surgeons survey","volume":"21","author":"Beitsch","year":"2014","journal-title":"Ann. Surg. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2018.12.021_bb0095","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2016.71.9260","article-title":"Multigene panel testing provides a new perspective on Lynch syndrome","volume":"35","author":"Espenschied","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0100","doi-asserted-by":"crossref","DOI":"10.1200\/CCI.18.00014","article-title":"Quality of clinician-reported cancer history when ordering genetic testing","author":"LaDuca","year":"2018","journal-title":"JCO Clinical Cancer Informatics"},{"issue":"2","key":"10.1016\/j.ygyno.2018.12.021_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcol.2013.04.004","article-title":"Historical review of Lynch syndrome","volume":"33","author":"Wolf","year":"2013","journal-title":"J. Coloproctol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.12.021_bb0110","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr3405","article-title":"Risk of breast cancer in Lynch syndrome: a systematic review","volume":"15","author":"Win","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/gim.2017.254","article-title":"MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer","author":"Roberts","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0120","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"The breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.ygyno.2018.12.021_bb0125","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","article-title":"The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study","volume":"104","author":"Beiner","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1375\/twin.14.2.111","article-title":"Report of endometrial cancer in Australian BRCA1 and BRCA2 mutation-positive families","volume":"14","author":"Duffy","year":"2011","journal-title":"Twin Res. Hum. Genet."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","article-title":"The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective study","volume":"130","author":"Segev","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.021_bb0145","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2018.12.021_bb0150","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ygyno.2018.12.021_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cge.12233","article-title":"Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation","volume":"85","author":"Metcalfe","year":"2014","journal-title":"Clin. Genet."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581831535X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581831535X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T03:11:36Z","timestamp":1552446696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581831535X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S009082581831535X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.12.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}